Anuh Pharma FY26 Net Profit Falls 13.3% to ₹4,104.61 Lakh

Anuh Pharma Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a net profit of ₹1,168.14 lakh for the quarter ended March 31, 2026, compared to ₹1,245.70 lakh in the corresponding period of the previous year. For the full financial year 2025-26, the net profit stood at ₹4,104.61 lakh, a decrease from ₹4,735.19 lakh in the previous year.

Revenue from operations for the quarter increased to ₹20,211.72 lakh from ₹19,813.95 lakh in the corresponding period of the previous year. On an annual basis, revenue rose to ₹77,165.74 lakh compared to ₹66,151.49 lakh in FY25. The total expenses for the year were reported at ₹72,179.16 lakh, up from ₹60,996.49 lakh in the prior year. The EBITDA for the year stood at ₹6,607.59 lakh, with an EBITDA margin of 8.56%.

Financial Performance

The following table presents the key financial metrics for the quarter and full year, reflecting the company's performance on a year-on-year basis. Notably, the Q4 EBITDA margin improved to 9.84% from 9.42% in the corresponding period of the previous year, indicating better operational efficiency at the quarterly level even as full-year profitability declined.

Metric:	Q4 FY26 (₹ in Lakhs)	Q4 FY25 (₹ in Lakhs)	FY26 (₹ in Lakhs)	FY25 (₹ in Lakhs)
Revenue from Operations	20,211.72	19,813.95	77,165.74	66,151.49
Total Expenses	18,534.31	18,225.81	72,179.16	60,996.49
EBITDA	1,862.82	2,006.92	6,607.59	7,036.40
EBITDA Margin	9.84%	9.42%	8.56%	—
Net Profit	1,168.14	1,245.70	4,104.61	4,735.19

The board approved the adoption of new Memorandum and Articles of Association, subject to shareholder approval. Additionally, the board approved the re-appointment of Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal as directors liable to retire by rotation. The company also appointed Mr. P. N. Rao as General Manager - Quality effective June 1, 2026. Furthermore, M/s. RMJ & Associates LLP were appointed as Internal Auditors and Ankit Kishor Chande was re-appointed as Cost Auditor for the financial year 2026-27.

Dividend Declaration

The board of directors recommended a final dividend of ₹1.50 per equity share, amounting to a 30% payout on the face value of ₹5 each for the financial year ended March 31, 2026. This dividend is subject to approval by shareholders at the ensuing Annual General Meeting. The record date for determining eligibility for the dividend has been fixed as August 5, 2026. The 66th Annual General Meeting is scheduled to be held on August 12, 2026, via Video Conferencing. The Register of Members and Share Transfer Books will remain closed from August 6, 2026, to August 12, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.94%	-2.93%	-5.98%	-4.12%	-27.84%	-31.54%

Anuh Pharma Limited has approved the reclassification of nine shareholders from the promoter group to the public category. The decision was made during the Board of Directors meeting held on May 20, 2026. The company had initially received requests from these shareholders on May 19, 2026, seeking the change in status under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The shareholders requesting the change collectively hold 9,49,988 equity shares, representing 0.95% of the company's total paid-up share capital. The applicants include individuals such as Kinjal Siddharth Jhaveri, who holds the largest portion among the applicants at 0.81%, and others like Nina Vijay Shah and Hemant Babubhai Choksi.

Details of Shareholders Seeking Reclassification

The following table outlines the shareholders approved for reclassification along with their respective holdings:

Sr No.	Name	Number of Equity shares held	% of shareholding
1.	Madhurika Narendra Shah	12,000	0.01
2.	Hemant Babubhai Choksi	24,000	0.02
3.	Mukesh Kantilal Shah	14,400	0.01
4.	Aruna Navnit Shah	5,040	0.01
5.	Vikram Kirtilal Shah	200	0.00
6.	Kiran Piyush Shah	15,388	0.02
7.	Kinjal Siddharth Jhaveri	8,16,160	0.81
8.	Nina Vijay Shah	60,000	0.06
9.	Neela Pradeep Shah	2,800	0.003
TOTAL		9,49,988	0.95

Regulatory Compliance and Undertakings

The Board confirmed that these individuals are immediate relatives of promoters and are no longer involved in the day-to-day affairs or management of anuh pharma . They stated that they do not exercise control over the company's affairs or possess special rights through formal or informal arrangements.

The outgoing promoters confirmed they do not hold more than 10% of the total voting rights, are not represented on the Board of Directors, and do not act as key managerial personnel. They also verified that they are not wilful defaulters or fugitive economic offenders, and there is no pending regulatory action against them.

Next Steps

The company will now take appropriate steps to secure the necessary approvals from stock exchanges. Once these approvals are received, the outgoing promoters will be officially reclassified as public shareholders.